Adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy did not improved event-free survival but increased overall survival in premenopausal women with triple-negative breast cancer, as shown by data recently published on The Journal of Clinical Oncology.
In this phase III trial, 717 patients with triple-negative breast cancer were randomly assigned to receive a neoadjuvant chemotherapy comprising once-per-week carboplatin plus paclitaxel for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. After a median follow-up of 67.6 months, carboplatin did not significantly increase event-free survival but significantly increased overall survival. The effect was seen only in premenopausal women, where 5-years event-free survival was 75% in the carboplatin group versus 59.6% in control group, and overall survival were 78.2% versus 64.6% respectively; pathological complete response was higher too (61.7% in the platinum arm versus 40.6% in the control arm). No benefit of adding platinum was seen in postmenopausal or over 50 years patients. Previous trials have found modest improvements in pathological complete response but inconsistent impact on event-free survival and overall survival; this trial adds to the accumulating data that platinum should be incorporated into curative treatment of triple-negative breast cancer. Aas authors conclude, «Adding carboplatin to a standard taxane-anthracycline neoadjuvant regimen in patients with triple-negative breast cancer did not significantly increase the event-free survival, but significantly increased the overall survival and pathological complete response, with a benefit confined to premenopausal patients».
Carboplatin added to sequential taxane-anthracycline in triple-negative breast cancer
Addition of carboplatin to sequential taxane-anthracycline neoadjuvant therapy increased overall survival in premenopausal women with triple-negative breast cancer
Adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy did not improved event-free survival but increased overall survival in premenopausal women with triple-negative breast cancer, as shown by data recently published on The Journal of Clinical Oncology.
In this phase III trial, 717 patients with triple-negative breast cancer were randomly assigned to receive a neoadjuvant chemotherapy comprising once-per-week carboplatin plus paclitaxel for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. After a median follow-up of 67.6 months, carboplatin did not significantly increase event-free survival but significantly increased overall survival. The effect was seen only in premenopausal women, where 5-years event-free survival was 75% in the carboplatin group versus 59.6% in control group, and overall survival were 78.2% versus 64.6% respectively; pathological complete response was higher too (61.7% in the platinum arm versus 40.6% in the control arm). No benefit of adding platinum was seen in postmenopausal or over 50 years patients. Previous trials have found modest improvements in pathological complete response but inconsistent impact on event-free survival and overall survival; this trial adds to the accumulating data that platinum should be incorporated into curative treatment of triple-negative breast cancer. Aas authors conclude, «Adding carboplatin to a standard taxane-anthracycline neoadjuvant regimen in patients with triple-negative breast cancer did not significantly increase the event-free survival, but significantly increased the overall survival and pathological complete response, with a benefit confined to premenopausal patients».